SHINE Medical Technologies will build its European medical isotope production facility in the Netherlands, the company announced today.

According to a release, the European facility, which will be located in the municipality of Veendam in the province of Groningen, will be focused initially on the production of molybdenum-99 (mo-99). Once complete, it, along with the U.S. plant, will be able to produce 70 percent of the global patient need.

“The selection of the location for our new European facility is another demonstration of SHINE’s commitment to being the world leader in the production of vital medical isotopes,” SHINE CEO Greg Piefer said in a statement. “We know that with our leadership comes a responsibility to European physicians and patients that we take seriously.”

Construction of the production facility is expected to begin in 2023, with commercial production to begin in late 2025.